What is the financial outlook for JNJ?
Next quarter's sales forecast for JNJ is $21.40B with a range of $21.11B to $21.80B. The previous quarter's sales results were $21.39B. JNJ beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.36% of the time in the same period.
What is the stock market outlook for Johnson and Johnson in 2024?
On average, analysts forecast that JNJ's EPS will be $10.65 for 2024, with the lowest EPS forecast at $10.57, and the highest EPS forecast at $10.70. On average, analysts forecast that JNJ's EPS will be $10.95 for 2025, with the lowest EPS forecast at $10.72, and the highest EPS forecast at $11.25.
What are analysts saying about JNJ?
Based on analysts offering 12 month price targets for JNJ in the last 3 months. The average price target is $174.8 with a high estimate of $215 and a low estimate of $155.
Should I hold or sell JNJ?
Is Johnson & Johnson stock a Buy, Sell or Hold? Johnson & Johnson stock has received a consensus rating of buy. The average rating score is Aaa and is based on 45 buy ratings, 32 hold ratings, and 1 sell ratings.
What is the financial forecast for Johnson and Johnson?
The 13 analysts with 12-month price forecasts for Johnson & Johnson stock have an average target of 166.92, with a low estimate of 40 and a high estimate of 215. The average target predicts an increase of 13.15% from the current stock price of 147.52. * Price targets were last updated on Mar 13, 2024.
What is the 5 year forecast for JNJ?
Johnson & Johnson stock price stood at $149.12
According to the latest long-term forecast, Johnson & Johnson price will hit $150 by the middle of 2024 and then $200 by the end of 2027. Johnson & Johnson will rise to $250 within the year of 2029 and $300 in 2032.
Is Johnson and Johnson a high risk stock?
Key Points. Johnson & Johnson is one of the top healthcare companies in the world, with a market cap of nearly $400 billion. The company, however, faces an uncertain future because of its unsettled talc lawsuits. The litigation could threaten its dividend and long-term growth prospects.
Is JNJ going to split up?
NEW BRUNSWICK, N.J., August 16, 2023 -- Johnson & Johnson (NYSE: JNJ) today announced the final exchange ratio for its previously announced split-off exchange offer to Johnson & Johnson shareholders to exchange their shares of Johnson & Johnson for shares of common stock of Kenvue Inc.
Is Johnson and Johnson financially healthy?
J&J, whose financial results are considered a bellwether for the broader health sector, booked $21.40 billion in total sales for the final three months of 2023, up 7.3% from the same quarter in 2022. The pharmaceutical giant reported net income of $4.13 billion, or $1.70 per share during the quarter.
Why is JNJ splitting?
The split allows J&J's executives to focus more on developing innovations and expanding the businesses of medical technologies and pharmaceuticals. “We need to be a top-tier medical tech company and a top-tier pharmaceutical company, first and foremost,” Chief Financial Officer Joseph Wolk said.
Who owns the most JNJ stock?
According to the latest TipRanks data, approximately 61.13% of Johnson & Johnson (JNJ) stock is held by retail investors. Vanguard owns the most shares of Johnson & Johnson (JNJ).
What will happen to JNJ shares?
What happens to JNJ stock when the company splits? Once Johnson and Johnson splits, JNJ stock will only give traders and investors exposure to the medical device and pharmaceutical proceeds of the company. The new company, which will be listed as Kenvue, will trade separately.
Is JNJ undervalued?
Intrinsic Value. The intrinsic value of one JNJ stock under the Base Case scenario is 156.07 USD. Compared to the current market price of 150.08 USD, Johnson & Johnson is Undervalued by 4%.
What will the JNJ stock price be in 2025?
| Year | Prediction | Change |
|---|---|---|
| 2025 | $ 156.36 | 5.70% |
| 2026 | $ 165.27 | 11.72% |
| 2027 | $ 174.68 | 18.08% |
| 2028 | $ 184.63 | 24.81% |
What are the top selling drugs of Johnson and Johnson?
The highest revenue generating drug is tsill Stelara which generated almost 11 billion U.S. dollars of revenue for the company.
Is JNJ a good long term stock?
Valuation metrics show that Johnson & Johnson may be undervalued. Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of JNJ, demonstrate its potential to outperform the market. It currently has a Growth Score of D.
Which is better to invest in Pfizer or Johnson and Johnson?
PFE's forward EV/Sales multiple of 2.94 is lower than JNJ's 4.35. PFE's forward EV/EBITDA multiple of 8.78x is lower than JNJ's 12.07x. PFE's trailing-12-month levered FCF margin of 8.29% is lower than JNJ's 23.23%. In addition, PFE's trailing-12-month asset turnover ratio of 0.33x is lower than JNJ's 0.48x.
Why should I buy JNJ stock?
Johnson & Johnson's JNJ biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. J&J has 25 platforms with more than $1 billion in annual sales.
Is JNJ in trouble?
J&J now faces at least 51,000 lawsuits claiming talc used in baby power and similar products caused cancer. Johnson & Johnson said it is weighing a third attempt to use bankruptcy for an $8.9 billion settlement of tens of thousands of lawsuits that allege tainted talc in the company's baby powder caused cancer.
What is the JNJ controversy?
In 2018, a Missouri court ordered Johnson & Johnson to pay nearly $4.7 billion to 22 women claiming asbestos in the company's talcum powder was linked to their cases of ovarian cancer.
What is the guidance for Johnson and Johnson in 2024?
Excluding certain items for the first quarter of 2024, adjusted earnings per share were $2.71. J&J also narrowed its full-year guidance for the year. The company now expects sales of $88 billion to $88.4 billion. That compares with a previous forecast of $87.8 billion to $88.6 billion.
What is the cash on hand for JNJ?
Cash on Hand as of December 2023 : $22.92 B
According to Johnson & Johnson's latest financial reports the company has $22.92 B in cash and cash equivalents.
What is JNJ earnings report for 2024?
| Q1 | ||
|---|---|---|
| ($ in Millions, except EPS) | 2024 | 2023 |
| Reported Sales | $21,383 | $20,894 |
| Net Earnings/(Loss) | $5,354 | ($491) |
| EPS (Diluted/Basic)6 | $2.20 | ($0.19) |
Why is JNJ spinning off consumer?
Why is Johnson and Johnson going to split? Johnson and Johnson's split is aimed at refocusing the business and streamlining its operations. By removing the consumer arm, Johnson and Johnson will put more into developing medicines and medical devices, which brought in around $80 billion for the firm combined.
Who bought J&J?
As previously announced, CBRE has purchased J&J for $800 million in cash, plus a potential earn-out of up to $250 million, payable in 2027, subject to the acquired business meeting certain performance thresholds. About CBRE Group, Inc.
